Cargando…

The effects of tricyclic antidepressants on breast cancer risk

To test the hypothesis that tricyclic antidepressant use increases invasive female breast cancer incidence, we carried out a case–control study within the population of female beneficiaries of the Saskatchewan Prescription Drug Plan aged ⩾35 years from 1981–1995 with no history of cancer since 1970....

Descripción completa

Detalles Bibliográficos
Autores principales: Sharpe, C R, Collet, J-P, Belzile, E, Hanley, J A, Boivin, J-F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746543/
https://www.ncbi.nlm.nih.gov/pubmed/11857018
http://dx.doi.org/10.1038/sj.bjc.6600013
_version_ 1782172046555348992
author Sharpe, C R
Collet, J-P
Belzile, E
Hanley, J A
Boivin, J-F
author_facet Sharpe, C R
Collet, J-P
Belzile, E
Hanley, J A
Boivin, J-F
author_sort Sharpe, C R
collection PubMed
description To test the hypothesis that tricyclic antidepressant use increases invasive female breast cancer incidence, we carried out a case–control study within the population of female beneficiaries of the Saskatchewan Prescription Drug Plan aged ⩾35 years from 1981–1995 with no history of cancer since 1970. This agency has provided full or partial coverage for outpatient prescriptions to Saskatchewan residents since 1975. We accrued 5882 histologically proven cases and 23 517 controls, randomly selected from the source population and individually matched on age and sampling time. Heavy exposure to any tricyclic antidepressants was associated with an elevated rate ratio for breast cancer 11–15 years later (2.02, 95% confidence interval: 1.34–3.04). Post hoc analyses based on the results of genotoxicity studies carried out using Drosophila melanogaster suggested that the increased risk could be attributed to the use of the six genotoxic tricyclic antidepressants, and not to the use of the four nongenotoxic tricyclic antidepressants. However, our results may have been confounded by the effects of other determinants of breast cancer associated with tricyclic antidepressant use. British Journal of Cancer (2002) 86, 92–97. DOI: 10.1038/sj/bjc/6600013 www.bjcancer.com © 2002 The Cancer Research Campaign
format Text
id pubmed-2746543
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27465432009-09-18 The effects of tricyclic antidepressants on breast cancer risk Sharpe, C R Collet, J-P Belzile, E Hanley, J A Boivin, J-F Br J Cancer Epidemiology To test the hypothesis that tricyclic antidepressant use increases invasive female breast cancer incidence, we carried out a case–control study within the population of female beneficiaries of the Saskatchewan Prescription Drug Plan aged ⩾35 years from 1981–1995 with no history of cancer since 1970. This agency has provided full or partial coverage for outpatient prescriptions to Saskatchewan residents since 1975. We accrued 5882 histologically proven cases and 23 517 controls, randomly selected from the source population and individually matched on age and sampling time. Heavy exposure to any tricyclic antidepressants was associated with an elevated rate ratio for breast cancer 11–15 years later (2.02, 95% confidence interval: 1.34–3.04). Post hoc analyses based on the results of genotoxicity studies carried out using Drosophila melanogaster suggested that the increased risk could be attributed to the use of the six genotoxic tricyclic antidepressants, and not to the use of the four nongenotoxic tricyclic antidepressants. However, our results may have been confounded by the effects of other determinants of breast cancer associated with tricyclic antidepressant use. British Journal of Cancer (2002) 86, 92–97. DOI: 10.1038/sj/bjc/6600013 www.bjcancer.com © 2002 The Cancer Research Campaign Nature Publishing Group 2002-01-07 /pmc/articles/PMC2746543/ /pubmed/11857018 http://dx.doi.org/10.1038/sj.bjc.6600013 Text en Copyright © 2002 The Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Epidemiology
Sharpe, C R
Collet, J-P
Belzile, E
Hanley, J A
Boivin, J-F
The effects of tricyclic antidepressants on breast cancer risk
title The effects of tricyclic antidepressants on breast cancer risk
title_full The effects of tricyclic antidepressants on breast cancer risk
title_fullStr The effects of tricyclic antidepressants on breast cancer risk
title_full_unstemmed The effects of tricyclic antidepressants on breast cancer risk
title_short The effects of tricyclic antidepressants on breast cancer risk
title_sort effects of tricyclic antidepressants on breast cancer risk
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746543/
https://www.ncbi.nlm.nih.gov/pubmed/11857018
http://dx.doi.org/10.1038/sj.bjc.6600013
work_keys_str_mv AT sharpecr theeffectsoftricyclicantidepressantsonbreastcancerrisk
AT colletjp theeffectsoftricyclicantidepressantsonbreastcancerrisk
AT belzilee theeffectsoftricyclicantidepressantsonbreastcancerrisk
AT hanleyja theeffectsoftricyclicantidepressantsonbreastcancerrisk
AT boivinjf theeffectsoftricyclicantidepressantsonbreastcancerrisk
AT sharpecr effectsoftricyclicantidepressantsonbreastcancerrisk
AT colletjp effectsoftricyclicantidepressantsonbreastcancerrisk
AT belzilee effectsoftricyclicantidepressantsonbreastcancerrisk
AT hanleyja effectsoftricyclicantidepressantsonbreastcancerrisk
AT boivinjf effectsoftricyclicantidepressantsonbreastcancerrisk